Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Moderna ( (MRNA) ).
On January 12, 2026, Moderna reported that it expected unaudited 2025 revenue of about $1.9 billion—slightly above prior guidance—alongside improved projected 2025 GAAP operating expenses of $5.0–$5.2 billion and an estimated year-end 2025 cash balance of $8.1 billion, supported in part by a $1.5 billion term loan facility. The company reiterated a framework of up to 10% revenue growth in 2026, further operating expense reductions through 2027 on a path to cash breakeven in 2028, and highlighted progress in its late-stage pipeline, including its approved mNEXSPIKE COVID vaccine, regulatory submissions and studies for RSV, flu, flu/COVID combination and norovirus vaccines, as well as advancing oncology candidates such as mRNA-4157 and mRNA-4359 and rare disease programs mRNA-3927 and mRNA-3705, underpinned by new funding support from Ares Management and CEPI for its H5 pandemic influenza candidate.
The most recent analyst rating on (MRNA) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Moderna stock, see the MRNA Stock Forecast page.
Spark’s Take on MRNA Stock
According to Spark, TipRanks’ AI Analyst, MRNA is a Neutral.
The score is held down primarily by weak financial performance (declining revenue, large losses, and negative operating/free cash flow). Support comes from a relatively strong balance sheet with low leverage and sizable cash, plus constructive technicals with the stock above major moving averages. Earnings-call execution on cost reductions and pipeline progress helps, but lowered revenue expectations and the CMV program discontinuation limit upside, while valuation remains unattractive due to ongoing losses.
To see Spark’s full report on MRNA stock, click here.
More about Moderna
Moderna is a biotechnology company specializing in messenger RNA (mRNA) medicines, developing vaccines and therapeutics across infectious diseases, cancer and rare diseases. Leveraging its mRNA platform and global operations, the company focuses on building a broad portfolio of seasonal vaccines while advancing late-stage oncology and rare disease programs to transform treatment and prevention of serious illnesses.
Average Trading Volume: 10,826,672
Technical Sentiment Signal: Hold
Current Market Cap: $13.23B
For an in-depth examination of MRNA stock, go to TipRanks’ Overview page.